ASBP logo

ASPIRE-LAKEWOOD HOLDINGS INC

ASBPNASDAQ
๐Ÿ† #4764 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track ASBP
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$10M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
-25.1%
Thin
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
102.4x
Expensive
Otter Score
โ€”
Insufficient data
No chart data available for ASBP.

Trading Snapshot

Day Range
โ€”
52-Week Range
$3.31 โ€“ $205.20
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
1.4M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$6,202
Last Q Revenue
$63,103
P/E Ratio
โ€”
P/S Ratio
102.4x
EPS (TTM)
$-121.90
Dividend Yield
โ€”
ASBP logo

ASPIRE-LAKEWOOD HOLDINGS INC

ASBP
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ASPIRE-LAKEWOOD HOLDINGS INC

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.